| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SAE1 |
| Uniprot No | Q9UBE0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-346aa |
| 氨基酸序列 | MVEKEEAGGGISEEEAAQYDRQIRLWGLEAQKRLRASRVLLVGLKGLGAE IAKNLILAGVKGLTMLDHEQVTPEDPGAQFLIRTGSVGRNRAEASLERAQ NLNPMVDVKVDTEDIEKKPESFFTQFDAVCLTCCSRDVIVKVDQICHKNS IKFFTGDVFGYHGYTFANLGEHEFVEEKTKVAKVSQGVEDGPDTKRAKLD SSETTMVKKKVVFCPVKEALEVDWSSEKAKAALKRTTSDYFLLQVLLKFR TDKGRDPSSDTYEEDSELLLQIRNDVLDSLGISPDLLPEDFVRYCFSEMA PVCAVVGGILAQEIVKALSQRDPPHNNFFFFDGMKGNGIVECLGPK |
| 预测分子量 | 65 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SAE1重组蛋白的3篇代表性文献示例(注：文献信息为模拟示例，实际检索请参考PubMed等数据库)：
---
1. **文献名称**: *"Recombinant expression and functional characterization of human SAE1/SAE2 heterodimer in SUMOylation"*
**作者**: Li X, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了人源SAE1与SAE2的异源二聚体重组蛋白，验证了其在体外SUMO激活及转移中的关键酶活性，为研究SUMO化修饰机制提供了工具。
2. **文献名称**: *"Structural insights into SAE1-mediated SUMO activation by X-ray crystallography"*
**作者**: Wang Y, et al.
**摘要**: 通过重组表达SAE1蛋白并进行晶体结构解析，揭示了SAE1与ATP结合的活性位点，阐明了其在SUMO激活酶复合体中的构象变化机制。
3. **文献名称**: *"Development of a SAE1 knockdown cell model using recombinant shRNA vectors"*
**作者**: Gupta R, et al.
**摘要**: 利用重组载体技术构建SAE1基因敲低细胞系，证实SAE1缺失导致细胞SUMO化水平显著降低，并诱发细胞周期停滞和凋亡现象。
---
**提示**：实际文献检索建议使用关键词 **"SAE1 recombinant"** 或 **"SAE1 SUMO activating enzyme"** 在PubMed/Google Scholar等平台筛选近年研究。
**Background of SAE1 Recombinant Protein**
SAE1 (SUMO-activating enzyme subunit 1) is a critical component of the SUMOylation pathway, a post-translational modification system essential for regulating diverse cellular processes. SUMO (Small Ubiquitin-like Modifier) proteins are covalently attached to target substrates via a cascade involving E1 (activating), E2 (conjugating), and E3 (ligase) enzymes. SAE1. in complex with SAE2. forms the heterodimeric E1 enzyme responsible for initiating SUMO activation. This step is ATP-dependent and facilitates the transfer of SUMO to the E2 enzyme UBC9. enabling subsequent substrate modification.
SUMOylation plays pivotal roles in maintaining genomic stability, modulating transcriptional regulation, and coordinating stress responses. Dysregulation of this pathway is implicated in cancers, neurodegenerative diseases, and immune disorders. SAE1. as a gatekeeper of SUMO activation, is thus a focal point for understanding disease mechanisms and therapeutic targeting.
Recombinant SAE1 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to produce purified, functional SAE1 for *in vitro* studies. Its recombinant form retains enzymatic activity, enabling researchers to dissect SUMOylation mechanics, screen inhibitors, or study interactions with SAE2 and UBC9. Structural analyses of SAE1 have also clarified its ATP-binding domain and conformational dynamics during SUMO activation.
Due to its centrality in SUMO biology, SAE1 recombinant protein is a vital tool for exploring cellular regulation and developing therapies targeting aberrant SUMOylation in pathologies. Ongoing research aims to harness its enzymatic properties for drug discovery and mechanistic insights into diseases linked to SUMO pathway dysregulation.
×
